These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30878532)

  • 1. Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey.
    Gultekin M; Karaca MZ; Kucukyildiz I; Dundar S; Keskinkilic B; Turkyilmaz M
    Papillomavirus Res; 2019 Jun; 7():118-122. PubMed ID: 30878532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
    Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
    BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
    Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
    BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
    Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
    J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for the most effective recall method in a cervical cancer screening program in Klang, Malaysia.
    Abdul Rashid RM; Dahlui M
    Asian Pac J Cancer Prev; 2013; 14(10):5867-70. PubMed ID: 24289591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis.
    Campos NG; Tsu V; Jeronimo J; Regan C; Resch S; Clark A; Sy S; Kim JJ
    Int J Cancer; 2019 Feb; 144(4):687-696. PubMed ID: 30132850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
    Cholli P; Bradford L; Manga S; Nulah K; Kiyang E; Manjuh F; DeGregorio G; Ogembo RK; Orock E; Liu Y; Wamai RG; Sheldon LK; Gona PN; Sando Z; Welty T; Welty E; Ogembo JG
    Gynecol Oncol; 2018 Jan; 148(1):118-125. PubMed ID: 29153541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a two-stage strategy with HPV testing followed by visual inspection with acetic acid for cervical cancer screening in a low-income setting.
    Tebeu PM; Fokom-Domgue J; Crofts V; Flahaut E; Catarino R; Untiet S; Vassilakos P; Petignat P
    Int J Cancer; 2015 Mar; 136(6):E743-50. PubMed ID: 25284599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study.
    Swanson M; Ibrahim S; Blat C; Oketch S; Olwanda E; Maloba M; Huchko MJ
    BMC Womens Health; 2018 Jul; 18(1):116. PubMed ID: 29970063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and challenges for introducing HPV testing for cervical cancer screening in sub-Saharan Africa.
    Tsu VD; Njama-Meya D; Lim J; Murray M; de Sanjose S
    Prev Med; 2018 Sep; 114():205-208. PubMed ID: 30031013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening.
    Darlin L; Borgfeldt C; Forslund O; Hénic E; Hortlund M; Dillner J; Kannisto P
    J Clin Virol; 2013 Sep; 58(1):155-60. PubMed ID: 23867008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
    Cubie HA; Moore C; Waller M; Moss S;
    J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Implementation of National Cervical Cancer Screening Program in France].
    Woronoff AS; Molinié F; Trétarre B
    Bull Cancer; 2019 Mar; 106(3):253-261. PubMed ID: 30635113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method].
    Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T
    Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.